SingleHealing & Recovery

GDF-8 / Myostatin 1mg

Laboratory reference ligand that functions as an endogenous negative regulator of skeletal muscle hypertrophy and tissue growth.

Mechanism

GDF-8 binds ActRIIB and ActRIIA receptor complexes to activate downstream Smad transcription factors, inhibiting skeletal muscle hypertrophy and repressing myofiber development.

Dosing

Standard reference calculations illustrate a baseline analytical aliquot of 50 mcg (0.05 mL / 5 units on a U-100 syringe) from a 1 mg/mL stock solution.

Reconstitution

Reconstituting a 1 mg vial with 1.0 mL of bacteriostatic water creates a laboratory stock solution calibrated to 1 mg/mL (1,000 mcg/mL).

Storage

Store unopened lyophilized vials refrigerated protected from light, and keep reconstituted aliquots strictly refrigerated at 2–8°C while avoiding repeated freeze-thaw cycles.

Mix & measure GDF-8 / Myostatin 1mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure GDF-8 / Myostatin 1mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.00mg/mL

Draw volume0.050mL

On the syringe5.00units

Total doses in vial: 20.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Reference Point 1	50 mcg (Analytical / Culture)	0.05 mL (5 units)
Reference Point 2	100 mcg (Analytical / Culture)	0.10 mL (10 units)
Reference Point 3	250 mcg (Analytical / Culture)	0.25 mL (25 units)
Reference Point 4	500 mcg (Analytical / Culture)	0.50 mL (50 units)

Reconstitution Steps

1
Inspect the certificate of analysis to verify whether the vial contains mature myostatin dimer or myostatin propeptide.
2
Sterilize the stoppers of both the bacteriostatic water vial and the peptide vial using fresh alcohol swabs.
3
Draw exactly 1.0 mL of bacteriostatic water using a sterile syringe.
4
Introduce the diluent steadily against the interior glass wall to minimize turbulent agitation against the lyophilizate.
5
Swirl the vial gently until completely dissolved without shaking to preserve tertiary protein structure.
6
Transfer into single-use microcentrifuge aliquots and store at 2–8°C protected from light.

Supplies Needed

Peptide Vial

Contains 1 mg of lyophilized recombinant GDF-8 / Myostatin reagent.

Insulin Syringes (U-100)

Used for precise volumetric measurement and dilution of liquid stock aliquots.

Bacteriostatic Water

Serves as the sterile reconstitution solvent to achieve a 1 mg/mL stock.

Alcohol Swabs

Used to disinfect vial septa and maintain aseptic laboratory conditions.

Why researchers study it

Regulation of skeletal muscle mass and myofiber dynamics

Screening and benchmarking candidate myostatin inhibitors

Assay calibrator for receptor-binding kinetics

Models of muscle wasting syndromes and cachexia

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Growth Differentiation Factor 8 (GDF-8), widely recognized as myostatin, is a member of the transforming growth factor-beta (TGF-β) superfamily expressed predominantly within skeletal muscle tissue. Historically identified as an autocrine and paracrine muscle-limiting signal, the peptide binds receptor complexes to halt protein synthesis and restrain muscular development. Consequently, research surrounding GDF-8 typically centers on blocking its endogenous action rather than administering the ligand itself. In contemporary laboratory experimentation, recombinant GDF-8 serves primarily as a standardized reference reagent. It is utilized in vitro to study activin receptor binding kinetics, benchmark downstream Smad signaling pathways, and calibrate assays intended to evaluate novel myostatin antagonists or follistatin mimetics. Systemic administration in preclinical animal models has been demonstrated to induce profound tissue wasting resembling cachexia, confirming its biological role as a physiological brake on muscle mass.

References

1.McPherron et al., Nature, 1997 — Identification of GDF-8 as a negative regulator of skeletal muscle mass in mice
2.Zimmers et al., Science, 2002 — Systemic overexpression of myostatin inducing cachexia and tissue wasting
3.Lee & McPherron, PNAS, 2001 — Regulation of myostatin activity, latency, and ActRIIB receptor binding
4.Wolfman et al., PNAS, 2003 — Cleavage and activation of latent myostatin by BMP-1/tolloid metalloproteinases
5.Lee, Annual Review of Physiology, 2022 — Comprehensive review of myostatin operating as a skeletal muscle chalone